Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

72.77 +2.50 (+3.55%)
Streaming Delayed Price Updated: 10:29 AM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Axsome Thera

< Previous 1 2 Next >
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AXSM
From The Rosen Law Firm, P.A.
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Axsome Therapeutics, Inc. (AXSM) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR DEADLINE: Axsome Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – AXSM
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
AXSM Shareholder Alert: Robbins LLP Reminds Investors of Class Action Against Axsome Therapeutics, Inc. (AXSM)
From Robbins LLP
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Axsome Therapeutics, Inc. (AXSM) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Axsome Therapeutics, Inc. (AXSM) Investors
From Law Offices of Howard G. Smith
Via Business Wire
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Axsome Therapeutics, Inc. (AXSM) Investors of Class Action and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Axsome Therapeutics, Inc. (AXSM) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Shareholder Alert: Did You Purchase Shares of Axsome Therapeutics, Inc. (AXSM)? Robbins LLP Alerts Investors of Class Action Against Axsome Therapeutics, Inc.
From Robbins LLP
Via Business Wire
AXSOME ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Axsome Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Axsome Therapeutics, Inc. (AXSM) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Axsome Therapeutics, Inc. (AXSM) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. with Losses of $500,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Axsome Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AXSM
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Axsome Therapeutics, Inc. With Losses of $500,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – AXSM
From The Rosen Law Firm, P.A.
Via Business Wire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Axsome Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shareholder Notice: Investigation over Possible Wrongdoing
San Diego, CA -- (SBWIRE) -- 09/29/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Axsome Therapeutics, Inc. 
Via SBWire
Exposures Product Safety
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shareholder Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 08/26/2021 -- Axsome Therapeutics, Inc is under investigation concerning possible securities laws violations in connection with certain financial statements. 
Via SBWire
Exposures Product Safety
CORRECTING and REPLACING Scott+Scott Attorneys at Law LLP Announces Investigation into Axsome Therapeutics Inc. (AXSM)
From Scott+Scott Attorneys at Law LLP
Via Business Wire
AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Axsome Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Scott+Scott Attorneys at Law LLP Announces Investigation into Axsome Therapeutics Inc. (AXSM)
From Scott+Scott Attorneys at Law LLP
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors With Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
AXSM INVESTOR ALERT: Rosen Law Firm Encourages Axsome Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation – AXSM
From The Rosen Law Firm, P.A.
Via Business Wire
Parkinson’s Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027
Via FinancialNewsMedia
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.